Clinical trials: sponsored by Juventas Cell Therapy Ltd.
Autoimmune Hemolytic Anemia (AIHA)
HY001N for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.
The goal of this clinical trial is to learn if HY001N cell injection safety and tolerability in adult patients with autoimmune hemolytic anemia after failure of 3 or more lines of therapy.
- Trial name
- NCT07748533
- Testing
- HY001N Cell Injection
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Juventas Cell Therapy Ltd.
Neurological Autoimmune Diseases
A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases
This study is a single-arm, open-label, non-randomized clinical trial aimed at evaluating the safety, tolerability and preliminary efficacy of CNCT19 cell injection in the treatment of patients with relapsed/refractory…
- Trial name
- NCT07275736
- Testing
- CNCT19 cell injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Juventas Cell Therapy Ltd.
Neurological Autoimmune Diseases
A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases
This study is a single-arm, open-label, non-randomized clinical trial aimed at evaluating the safety, tolerability and preliminary efficacy of HY001N cell injection in the treatment of patients with relapsed/refractory…
- Trial name
- NCT07265206
- Testing
- HY001N cell injection
- Volunteers
- 15 people
- Sponsor
- Juventas Cell Therapy Ltd.
AIHA - Cold Autoimmune Hemolytic Anemia
Inaticabtagene Autoleucel Injection in the Treatment of Autoimmune Hemolytic Anemia After Three or More Lines of Therapy
This is a multicenter, open-label, single-arm Phase I clinical trial to evaluate the safety and tolerability of Inaticabtagene Autoleucel Injection treatment in autoimmune hemolytic anemia that has failed at least three lines of…
- Trial name
- NCT07091370
- Testing
- Inaticabtagene Autoleucel Injection
- Volunteers
- 12 people
- Sponsor
- Juventas Cell Therapy Ltd.
B-cell Acute Lymphoblastic Leukemia
A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
This is a multi-center, phase Ib/II trial to evaluate the safety and efficacy of CNCT19 treatment in Children and Adolescent (pediatric) patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-cell ALL).
- Trial name
- NCT05667506
- Testing
- single dose of CNCT19
- Where
- 9 sites in China
- Volunteers
- 47 people
- Sponsor
- Juventas Cell Therapy Ltd.
Non-hodgkin Lymphoma
Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
This is a multi-center, open-label, single-arm, phase I/II trial to evaluate the safety and efficacy of HY004 treatment in Adult patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma (r/r B-NHL).
- Trial name
- NCT06005649
- Testing
- HY004
- Sponsor
- Juventas Cell Therapy Ltd.
B-cell Acute Lymphoblastic Leukemia
A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)
This is a multi-center, phase I/II trial to evaluate the safety and efficacy of HY004 treatment in Adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-cell ALL).
- Trial name
- B-ALL (NCT06009107)
- Testing
- HY004, Cyclophosphamide, Fludarabine Phosphate
- Sponsor
- Juventas Cell Therapy Ltd.
Relapsed or Refractory Acute Lymphoblastic Leukemia
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of CD19 positive Relapsed or Refractory acute…
- Trial name
- NCT04684147
- Testing
- single dose of CNCT19
- Where
- 11 sites in China
- Volunteers
- 100 people
- Sponsor
- Juventas Cell Therapy Ltd.
B-cell Tumors
Long-term Observational Study of Patients Treated With Inaticabtagene Autoleucel Injection
This clinical trial adopts an observational research method to conduct annual follow-up and monitoring of patients receiving treatment with Inaticabtagene Autoleucel Injection after its commercialization, in order to evaluate the…
- Trial name
- NCT06461351
- Testing
- Inaticabtagene autoleucel Injection
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Juventas Cell Therapy Ltd.
Autoimmune Thrombocytopenia
Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia
This is a single-arm, open-label，phase I clinical study to evaluate the safety and tolerability of Inaticabtagene Autoleucel Injection in treatment of refractory systemic lupus erythematosus-related immune thrombocytopenia.
- Trial name
- NCT06826430
- Testing
- Inaticabtagene autoleucel Injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Juventas Cell Therapy Ltd.
Lupus Erythematosus, Systemic
Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases
Exploratory clinical study of CNCT19 anti CD19 cell therapy in the treatment of refractory autoimmune diseases,To evaluate the safety and tolerability of CNCT19 in patients with refractory systemic lupus erythematosus (lupus…
- Trial name
- NCT06316791
- Testing
- single dose of CNCT19
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Juventas Cell Therapy Ltd.
Non-Hodgkin's Lymphoma
Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of relapsed or refractory NHL.
- Trial name
- NCT04586478
- Testing
- single dose of CNCT19
- Where
- 17 sites in China
- Volunteers
- 60 people
- Sponsor
- Juventas Cell Therapy Ltd.
B-cell Acute Lymphoblastic Leukemia
Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
This clinical trial is a non-interventional, observational, multicenter, post-marketing real-world study to evaluate the efficacy and safety of Inaticabtagene Autoleucel Injection in Chinese adult patients with relapsed or…
- Trial name
- NCT06450067
- Where
- 10 sites in China
- Volunteers
- 200 people
- Sponsor
- Juventas Cell Therapy Ltd.
Diffuse Non-Hodgkin Lymphoma
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma
This is a single arm, open-label, non-randomized, dose-escalation, phase I study to determine the safety and efficacy of CNCT19 in adult patients with relapsed or refractory diffuse Non-Hodgkin lymphoma.
- Trial name
- NCT04232826
- Testing
- single dose of CNCT19
- Where
- 2 sites in China
- Volunteers
- 9 people
- Sponsor
- Juventas Cell Therapy Ltd.
Relapsed or Refractory Acute Lymphoblastic Leukemia
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
This is a single arm, open-label, non-randomized, dose-escalation, phase I study to determine the safety and efficacy of CNCT19 in adult patients with relapsed or refractory acute lymphoblastic leukemia.
- Trial name
- NCT04230473
- Testing
- single dose of CNCT19
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Juventas Cell Therapy Ltd.